I have been a bit cynical/cautious about this company to date, but these sound like excellent results with proper readout in the not too distant future. if it works for treatment of infection in wounds (and doesn't somehow adversely effect healing) then it has potential even if (in the worst case) intravenous applications never get off the ground.
May have to change rating to "back the truck up".
Ann: Update on Phase I/II Clinical Trial for Burn Wound Infection, page-27
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.5¢ | $17.85K | 47.61K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 8699 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 174 | 1 |
View Market Depth
| Last trade - 13.31pm 08/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |